Yucui Li on Muck Rack

Yucui Li

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yucui

Contact Yucui, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Low dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trial

|
By Xia Zhang, Ruiling Feng, Yifan Wang Verified, Wenqiang Fan, Xiao Gao, Miaomiao Ma, Dongbin Jiang, Ting Li, Huifang Guo, Lingyan Lei, Ke Xu, Wei Wei, Na Zhang, Wenping Pan, Qingwen Wang, Juan He, Ruijun Zhang, Rong Mu, Yongfu Wang, Hui Wang, Yuan Jia, Xiaolin Sun, Zhanguo Li, Jing He, Guanmin Gao, Yucui Li, Kuanting Wang, Yueming Cai, Tongjun Mao
| Nature Verified
Abstract Low-dose interleukin 2 (Ld-IL2) has shown therapeutic effects in autoimmune diseases, particularly systemic lupus erythematosus (SLE), yet optimal dosage has not been established in clinical trials. In this multicentre, double-blind, phase IIb trial, 152 patients with active SLE were randomised (1:1:1:1) to receive subcutaneous IL2 (0.2, 0.5, or 1.0 million IU) or placebo every other day for 12 weeks, then weekly for another 12 weeks.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified